Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Univ. Licenses Barrett’s Esophagus Detection Device

Cancer magnified

A medical device company is licensing a minimally-invasive technology developed in university labs for detection of Barrett’s esophagus, a condition that often leads to esophageal cancer. . . . → Read More: Univ. Licenses Barrett’s Esophagus Detection Device

Univ. Spinoff Qualifies for NIH Clinical Program

Kate Rittenhouse-Olson and John Fisk

An enterprise developing a synthetic antibody to treat breast cancer, spun-off from a University at Buffalo research lab, is taking part in a federal program to advance the treatments to clinical trials. . . . → Read More: Univ. Spinoff Qualifies for NIH Clinical Program

3-D Models Devised to Simulate Patients’ Tumors

Gioeli lab group

A university lab is teaming up with a local biotechnology company to develop realistic models of tumors from individual cancer patients, enabling more personalized treatment options. . . . → Read More: 3-D Models Devised to Simulate Patients’ Tumors

Fitness Trackers Seen Feasible for Cancer Patients

Arjun Gupta and Muhammad Beg

Activity tracking devices, used by athletes and ordinary persons to track their fitness, are shown in a pilot test to successfully monitor physical activity of older cancer patients for periods of 10 weeks or more. . . . → Read More: Fitness Trackers Seen Feasible for Cancer Patients

Bio-Inspired Surgical Camera Highlights Cancer Tissue

A camera modeled on capabilities of a butterfly’s eye offers surgeons definitive images of tumor tissue for removal, as demonstrated in tests with lab animals and patients with breast cancer. . . . → Read More: Bio-Inspired Surgical Camera Highlights Cancer Tissue

New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells. . . . → Read More: New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

Cough Suppressant Produced from Engineered Yeast Cells

A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast. . . . → Read More: Cough Suppressant Produced from Engineered Yeast Cells

Antibodies Licensed for Multi-Target Immunotherapies

MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets. . . . → Read More: Antibodies Licensed for Multi-Target Immunotherapies

High False-Positive Rate Found in Consumer Genetic Tests

Follow-up reviews of results from direct-to-consumer genetic tests show 40 percent of the actionable gene variations reported in the tests, including some indicating disease risk, were erroneous. . . . → Read More: High False-Positive Rate Found in Consumer Genetic Tests

Immune Disease Precision Therapy Company Starts Up

An enterprise to discover biomarkers and precise treatments for individuals with immune system disorders is starting up, founded by six researchers in the U.S. and Europe. . . . → Read More: Immune Disease Precision Therapy Company Starts Up